Feiby L Nassan1, Brent A Coull2, Niels E Skakkebaek3, Michelle A Williams4, Ramace Dadd5, Lidia Mínguez-Alarcón5, Stephen A Krawetz6, Elizabeth J Hait7, Joshua R Korzenik8, Alan C Moss9, Jennifer B Ford5, Russ Hauser10. 1. Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA. Electronic address: fen769@mail.harvard.edu. 2. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 3. University Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 5. Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 6. Department of Obstetrics & Gynecology, Center for Molecular Medicine & Genetics, Wayne State University, Detroit, MI, USA. 7. Division of Gastroenterology, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA. 8. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 9. Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 10. Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Vincent Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Phthalates are widely used chemicals with ubiquitous exposure. Dibutyl-phthalate (DBP), a male reproductive toxicant in animals, is understudied in humans. Some mesalamine medications used to treat inflammatory bowel disease (IBD) have DBP in their coating, whereas other mesalamine formulations do not. OBJECTIVES: Taking advantage of differences in mesalamine formulations, we investigated whether high-DBP exposure from mesalamine medications was associated with decreased semen parameters. METHODS: 73 men with IBD taking mesalamine participated in a crossover-crossback prospective study. Men taking non-DBP containing mesalamine at baseline i.e., background exposure, crossed-over for four months to high-DBP mesalamine and then crossed-back for four months to their non-DBP mesalamine (B1HB2-arm;Background1-High-Background2) and vice versa for men taking high-DBP mesalamine at baseline (H1BH2-arm;High1-Background-High2). Men provided up to six semen samples (2: baseline, 2: crossover and 2: crossback). RESULTS: We estimated crossover, crossback and carryover effects using linear mixed models adjusted for abstinence time, age, season and duration on high-DBP mesalamine at baseline. Semen parameters in B1HB2-arm (26 men, 133 samples) decreased after high-DBP mesalamine exposure (crossover versus baseline), especially motility parameters, and continued to decrease further even after crossback to non-DBP mesalamine (crossback versus crossover). The cumulative carryover effect of high-DBP (crossback versus baseline) was a decrease of % total sperm motility by 7.61(CI:-13.1, -2.15), % progressive sperm motility by 4.23(CI:-8.05, -0.4) and motile sperm count by 26.0% (CI:-46.2%, 1.7%). However, H1BH2-arm (47 men, 199 samples) had no significant change during crossover or crossback. CONCLUSIONS: Men newly exposed to high-DBP mesalamine for four months had a cumulative reduction in several semen parameters, primarily sperm motility, that was more pronounced and statistically significant even after exposure ended for four months.
BACKGROUND:Phthalates are widely used chemicals with ubiquitous exposure. Dibutyl-phthalate (DBP), a male reproductive toxicant in animals, is understudied in humans. Some mesalamine medications used to treat inflammatory bowel disease (IBD) have DBP in their coating, whereas other mesalamine formulations do not. OBJECTIVES: Taking advantage of differences in mesalamine formulations, we investigated whether high-DBP exposure from mesalamine medications was associated with decreased semen parameters. METHODS: 73 men with IBD taking mesalamine participated in a crossover-crossback prospective study. Men taking non-DBP containing mesalamine at baseline i.e., background exposure, crossed-over for four months to high-DBPmesalamine and then crossed-back for four months to their non-DBPmesalamine (B1HB2-arm;Background1-High-Background2) and vice versa for men taking high-DBPmesalamine at baseline (H1BH2-arm;High1-Background-High2). Men provided up to six semen samples (2: baseline, 2: crossover and 2: crossback). RESULTS: We estimated crossover, crossback and carryover effects using linear mixed models adjusted for abstinence time, age, season and duration on high-DBPmesalamine at baseline. Semen parameters in B1HB2-arm (26 men, 133 samples) decreased after high-DBPmesalamine exposure (crossover versus baseline), especially motility parameters, and continued to decrease further even after crossback to non-DBPmesalamine (crossback versus crossover). The cumulative carryover effect of high-DBP (crossback versus baseline) was a decrease of % total sperm motility by 7.61(CI:-13.1, -2.15), % progressive sperm motility by 4.23(CI:-8.05, -0.4) and motile sperm count by 26.0% (CI:-46.2%, 1.7%). However, H1BH2-arm (47 men, 199 samples) had no significant change during crossover or crossback. CONCLUSIONS:Men newly exposed to high-DBPmesalamine for four months had a cumulative reduction in several semen parameters, primarily sperm motility, that was more pronounced and statistically significant even after exposure ended for four months.
Authors: Julia J Wirth; Mary G Rossano; Rachel Potter; Elizabeth Puscheck; Douglas C Daly; Nigel Paneth; Stephen A Krawetz; Bridget M Protas; Michael P Diamond Journal: Syst Biol Reprod Med Date: 2008 May-Jun Impact factor: 3.061
Authors: Manori J Silva; Dana B Barr; John A Reidy; Nicole A Malek; Carolyn C Hodge; Samuel P Caudill; John W Brock; Larry L Needham; Antonia M Calafat Journal: Environ Health Perspect Date: 2004-03 Impact factor: 9.031
Authors: Feiby L Nassan; Lidia Mínguez-Alarcón; Paige L Williams; Ramace Dadd; John C Petrozza; Jennifer B Ford; Antonia M Calafat; Russ Hauser Journal: Environ Res Date: 2019-08-06 Impact factor: 6.498
Authors: Feiby L Nassan; Jorge E Chavarro; Lidia Mínguez-Alarcón; Paige L Williams; Cigdem Tanrikut; Jennifer B Ford; Ramace Dadd; Melissa J Perry; Russ Hauser; Audrey J Gaskins Journal: Int J Hyg Environ Health Date: 2018-05-22 Impact factor: 5.840
Authors: Feiby L Nassan; Tim I M Korevaar; Brent A Coull; Niels E Skakkebæk; Stephen A Krawetz; Molly Estill; Elizabeth J Hait; Joshua R Korzenik; Jennifer B Ford; Ralph A De Poortere; Maarten A Broeren; Alan C Moss; Thomas R Zoeller; Russ Hauser Journal: Int J Hyg Environ Health Date: 2018-08-28 Impact factor: 5.840
Authors: Feiby L Nassan; Brent A Coull; Niels E Skakkebaek; Anna-Maria Andersson; Michelle A Williams; Lidia Mínguez-Alarcón; Stephen A Krawetz; Janet E Hall; Elizabeth J Hait; Joshua R Korzenik; Jennifer B Ford; Alan C Moss; Russ Hauser Journal: Environ Res Date: 2017-10-01 Impact factor: 6.498
Authors: Elizabeth Cullen; David Evans; Chris Griffin; Padraig Burke; Rory Mannion; Damien Burns; Andrew Flanagan; Ann Kellegher; Greet Schoeters; Eva Govarts; Pierre Biot; Ludwine Casteleyn; Argelia Castaño; Marike Kolossa-Gehring; Marta Esteban; Gerda Schwedler; Holger M Koch; Jürgen Angerer; Lisbeth E Knudsen; Reinhard Joas; Anke Joas; Birgit Dumez; Ovnair Sepai; Karen Exley; Dominique Aerts Journal: Int J Environ Res Public Health Date: 2017-11-25 Impact factor: 3.390
Authors: Giovanna Tranfo; Lidia Caporossi; Daniela Pigini; Silvia Capanna; Bruno Papaleo; Enrico Paci Journal: Int J Environ Res Public Health Date: 2018-09-06 Impact factor: 3.390